Product Description
Resminostat is an orally administered histone deacetylase (HDAC) inhibitor that potentially represents a novel therapy for a broad spectrum of oncology indications, both in monotherapy and particularly in combination with other anti-cancer drugs. (Sourced from: https://www.4sc.com/product-pipeline/resminostat/)
Mechanisms of Action: HDAC Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: 4SC
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Austria, Belgium, France, Germany, Greece, Italy, Japan, Netherlands, Poland, Spain, Switzerland, United Kingdom
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Mycosis Fungoides|Sezary Syndrome|T-Cell Cutaneous Lymphoma
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT02953301 |
RESMAIN | P2 |
Completed |
T-Cell Cutaneous Lymphoma|Mycosis Fungoides|Sezary Syndrome |
2023-03-01 |
65% |
2024-09-04 |
Primary Endpoints|Study Completion Date|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
12/12/2024 |
News Article |
Cutaneous T-Cell Lymphoma Diagnosis Market Set to Surpass US$ 425.8 Million by 2034, States Fact.MR |
|
04/11/2024 |
PubMed |
Staphylococcus aureus induces drug resistance in cancer T cells in Sézary syndrome. |
|
02/20/2022 |
PubMed |
Combination of Resminostat with Ruxolitinib Exerts Antitumor Effects in the Chick Embryo Chorioallantoic Membrane Model for Cutaneous T Cell Lymphoma. |
|
10/19/2021 |
PubMed |
Metabolism-Associated Epigenetic and Immunoepigenetic Reprogramming in Liver Cancer. |
|
08/06/2021 |
News Article |
Cutaneous T-Cell Lymphoma Drug Pipeline Landscape Report 2021 - ResearchAndMarkets.com |
|
06/15/2021 |
News Article |
Global Cutaneous T-Cell Lymphoma (CTCL) Clinical Landscape Market Report 2021-2031 - ResearchAndMarkets.com |
|
06/14/2021 |
News Article |
Global T-Cell Lymphoma Pipeline Market Report 2021 - ResearchAndMarkets.com |